Amicus Therapeutics, Inc. (FOLD) Major Shareholder Life Sciences Maste Perceptive Buys 50,000 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) major shareholder Life Sciences Maste Perceptive acquired 50,000 shares of the business’s stock in a transaction dated Friday, September 21st. The stock was purchased at an average cost of $12.53 per share, for a total transaction of $626,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Wednesday, September 12th, Life Sciences Maste Perceptive acquired 500,000 shares of Amicus Therapeutics stock. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $6,000,000.00.

Shares of Amicus Therapeutics stock opened at $12.19 on Wednesday. Amicus Therapeutics, Inc. has a one year low of $11.57 and a one year high of $17.62. The company has a quick ratio of 10.73, a current ratio of 10.88 and a debt-to-equity ratio of 0.30.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The firm had revenue of $21.31 million for the quarter, compared to the consensus estimate of $18.92 million. analysts forecast that Amicus Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Several analysts recently commented on the company. BidaskClub lowered Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 18th. Chardan Capital lowered Amicus Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $18.00 to $15.00 in a report on Friday, August 17th. ValuEngine raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. Finally, Zacks Investment Research lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.43.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in Amicus Therapeutics by 6.1% during the second quarter. BlackRock Inc. now owns 16,017,301 shares of the biopharmaceutical company’s stock worth $250,190,000 after buying an additional 927,049 shares in the last quarter. Redmile Group LLC increased its stake in Amicus Therapeutics by 7.1% during the first quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock worth $161,509,000 after acquiring an additional 712,888 shares during the last quarter. Palo Alto Investors LP increased its stake in Amicus Therapeutics by 2.4% during the first quarter. Palo Alto Investors LP now owns 6,147,829 shares of the biopharmaceutical company’s stock worth $92,463,000 after acquiring an additional 141,807 shares during the last quarter. Morgan Stanley increased its stake in Amicus Therapeutics by 519.6% during the second quarter. Morgan Stanley now owns 4,968,627 shares of the biopharmaceutical company’s stock worth $77,610,000 after acquiring an additional 4,166,756 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Amicus Therapeutics by 1.3% during the first quarter. Franklin Resources Inc. now owns 3,767,389 shares of the biopharmaceutical company’s stock worth $56,661,000 after acquiring an additional 48,490 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Read More: Risk Tolerance

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply